Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Riedel, R, Michels, S, Heydt, C, Siemanowski, J, Kobe, C, Bunck, A, Schäfer, S, Fischer, RN, Scheffler, M, Abdulla, DSY, Nogová, L, Koleczko, S, Merkelbach-Bruse, S, Büttner, R, and Wolf, J. "Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma(Accepted)." Lung Cancer 133 (July 1, 2019): 20-22.
Riedel, R, Michels, S, Heydt, C, Siemanowski, J, Kobe, C, Bunck, A, Schäfer, S, Fischer, RN, Scheffler, M, Abdulla, DSY, Nogová, L, Koleczko, S, Merkelbach-Bruse, S, Büttner, R, and Wolf, J. "Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma(Accepted)." Lung Cancer 133 (July 1, 2019): 20-22.
Riedel, R., S. Michels, C. Heydt, J. Siemanowski, C. Kobe, A. Bunck, S. Schäfer, et al. “Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.” Lung Cancer 133 (July 1, 2019): 20–22. https://doi.org/10.1016/j.lungcan.2019.05.006.
Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors..” In Cancer Chemother Pharmacol, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.
PMID
30895346
Robinson, Timothy J., Jennifer A. Freedman, Muthana Al Abo, April E. Deveaux, Bonnie LaCroix, Brendon M. Patierno, Daniel J. George, and Steven R. Patierno. “Alternative RNA Splicing as a Potential Major Source of Untapped Molecular Targets in Precision Oncology and Cancer Disparities..” Clin Cancer Res 25, no. 10 (May 15, 2019): 2963–68. https://doi.org/10.1158/1078-0432.CCR-18-2445.
PMID
30755441
Crosby, Erika J., William Gwin, Kimberly Blackwell, Paul K. Marcom, Serena Chang, Holden T. Maecker, Gloria Broadwater, et al. “Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study..” Clin Cancer Res 25, no. 9 (May 1, 2019): 2725–36. https://doi.org/10.1158/1078-0432.CCR-18-3102.
PMID
30635338
Wang, Xiaoli, Shuo Wang, Michael A. Morse, Ni Jiang, Yanjie Zhao, Yuguang Song, Lei Zhou, et al. “Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients..” J Thromb Thrombolysis 47, no. 4 (May 2019): 505–11. https://doi.org/10.1007/s11239-019-01844-7.
PMID
30903459
Hurria, Arti, Enrique Soto-Perez-de-Celis, Jacob B. Allred, Harvey Jay Cohen, Anait Arsenyan, Karla Ballman, Jennifer Le-Rademacher, et al. “Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer..” J Am Geriatr Soc 67, no. 5 (May 2019): 920–27. https://doi.org/10.1111/jgs.15493.
PMID
30146695
Sonpavde, Guru, Neeraj Agarwal, Gregory Russell Pond, Rebecca J. Nagy, Roberto H. Nussenzveig, Andrew W. Hahn, Oliver Sartor, et al. “Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer..” Cancer 125, no. 9 (May 1, 2019): 1459–69. https://doi.org/10.1002/cncr.31959.
PMID
30620391
Fujiwara, Yutaka, Haruo Iguchi, Noboru Yamamoto, Manabu Hayama, Masahiro Nii, Shinya Ueda, Keiko Komuro, Mariko Sugimoto, Gordana Vlahovic, and Toshiyuki Kozuki. “Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors..” Cancer Sci 110, no. 5 (May 2019): 1715–23. https://doi.org/10.1111/cas.14003.
PMID
30891877